Emerging Precision and Off-Label Therapies in Medical Dermatology

Conclusions

• The presentation argues that dermatology is moving toward precision medicine, where treatment is increasingly guided by genetic and inflammatory signatures rather than diagnosis alone.
• It suggests that identifying a disease’s dominant pathway can help repurpose existing biologic and small-molecule therapies for difficult skin diseases.
• For bullous pemphigoid and some pemphigus cases, the talk concludes that dupilumab may be a useful and generally safe off-label option, especially when standard therapies are limited or insurers permit coverage.
• For cutaneous lupus and juvenile dermatomyositis, interferon-pathway blockade with anifrolumab appears promising, with multiple reports showing meaningful clinical improvement in refractory disease.
• The brepocitinib phase 3 trial is presented as strong evidence that dual JAK/TYK2 inhibition may become an important future therapy for dermatomyositis because it produced rapid and substantial improvement.
• The discussion concludes that granuloma annulare and related granulomatous disorders may respond to JAK-pathway inhibition, but the evidence is still mostly early and based on small studies or case reports.
• The presentation suggests that sarcoidosis and granulomatous dermatitis may also benefit from targeted therapies such as mTOR inhibition, TYK2 inhibition, or topical JAK inhibition, though the data remain preliminary.
• It concludes that baricitinib can be effective for pediatric necrobiosis lipoidica when corticosteroids fail.
• The speaker’s review implies that upadacitinib may be a plausible rescue therapy for recalcitrant extraintestinal Crohn-related skin disease and possibly even toxic epidermal necrolysis, but the evidence is too limited to be definitive.
• Overall, the talk concludes that many refractory inflammatory and granulomatous dermatoses may eventually be managed with pathway-directed agents, but most current uses remain off-label and supported mainly by small studies and case reports.